11 Feb '21
MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the pricing of its initial public offering of 13,800,000 shares of
27 Jan '21
Clinician and Academician Brings Expertise in Women's and Adolescents' Health and Focus on Diversity, Equity, and Inclusion MENLO PARK, Calif., Jan. 27, 2021 /PRNewswire/ --  Talis Biomedical Corporation , a company dedicated to developing innovative molecular diagnostic tests for infectious